Triomics raises $22M to deploy oncology AI across cancer centers

Triomics has secured $22 million in a Series B funding round led by Battery Ventures to expand its oncology-specific artificial intelligence platform. The startup aims to bring AI-driven tools to cancer centers to improve patient care and clinical workflows.

US-based health tech startup Triomics has closed a $22 million Series B funding round, with Battery Ventures leading the investment. The capital will be used to accelerate the deployment of the company's oncology-focused artificial intelligence platform across cancer treatment centers.

Triomics develops AI tools specifically designed for oncology workflows, helping cancer centers streamline clinical operations and improve how patient data is processed and acted upon. Unlike general-purpose medical AI, the platform is built from the ground up with the complexity of cancer care in mind — covering everything from patient intake to treatment decision support.

The funding comes at a time when healthcare systems globally are under pressure to handle growing patient volumes while managing costs. AI-driven platforms purpose-built for specialty medicine, like oncology, are increasingly seen as a solution to reduce administrative burden and surface clinically relevant insights faster.

Battery Ventures' decision to lead the round signals strong investor confidence in vertical AI — artificial intelligence tailored to specific industries rather than broad general use. Oncology, with its highly specialized data and complex care pathways, represents one of the more demanding and high-value areas for such focused AI development.

Triomics joins a growing wave of healthcare AI startups attracting significant venture capital as the sector matures beyond hype into practical clinical applications. With the new funding, the company is expected to expand its team and deepen partnerships with cancer centers across the United States.